[{"id":"c6520123-3091-4e6d-9609-b12e42d32d50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04205838","created_at":"2024-05-08T20:28:52.767Z","updated_at":"2025-02-25T15:43:48.249Z","phase":"Phase 2","brief_title":"Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT04205838","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Kineret (anakinra)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-12-13"},{"id":"07140c11-1fde-4d36-884f-c54317f0764e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01802970","created_at":"2021-01-18T07:59:02.642Z","updated_at":"2024-07-02T16:36:23.255Z","phase":"Phase 1","brief_title":"Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT01802970","lead_sponsor":"Baylor Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • Kineret (anakinra)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 01/04/2017","primary_completion_date":" 01/04/2017","study_txt":" Completion: 01/04/2017","study_completion_date":" 01/04/2017","last_update_posted":"2021-10-08"},{"id":"b9949f74-e4d6-4f59-8592-9d6c650b15e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926467","created_at":"2021-06-15T17:53:15.026Z","updated_at":"2024-07-02T16:36:29.057Z","phase":"Phase 2","brief_title":"Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT04926467","lead_sponsor":"Baylor Research Institute","biomarkers":" IL6 • IL1A • IL1B • CA 19-9","pipe":"","alterations":" ","tags":["IL6 • IL1A • IL1B • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • albumin-bound paclitaxel • oxaliplatin • irinotecan • Kineret (anakinra)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2021-06-15"},{"id":"5c2cbde9-e9f3-4aed-9b70-b82869671684","acronym":"","url":"https://clinicaltrials.gov/study/NCT04691765","created_at":"2021-01-19T20:48:46.572Z","updated_at":"2024-07-02T16:36:33.049Z","phase":"Phase 1","brief_title":"Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04691765","lead_sponsor":"Dr. David Spaner","biomarkers":" CD20 • IGH • CD5","pipe":"","alterations":" ","tags":["CD20 • IGH • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kineret (anakinra)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-03-19"}]